Frequently Asked Questions

SPRITAM is available in 250 mg. Learn more.

No, SPRITAM does not contain any gluten or dyes.

Mannitol is one of the inactive ingredients contained in SPRITAM. Mannitol is derived from cornstarch. Therefore, SPRITAM may contain negligible amounts of corn-based material. If your patient is allergic to corn, you should consider whether or not they should avoid products containing or derived from cornstarch.

SPRITAM does not contain soy, although it may contain negligible amounts of soy-based material. One of the inactive ingredients, butylated hydroxyanisole, contains refined soy oil. If your patient is allergic to soy, you should consider whether or not they should avoid products containing or derived from refined soy oil.

SPRITAM contains two sugar alcohols, mannitol and glycerin. Their calorie and carbohydrate impact is negligible. At the maximum recommended daily dose of 3,000 mg/day, SPRITAM would contribute no more than 1 calorie and approximately 0.25 grams of carbohydrates based upon the amount of glycerin and mannitol that would be consumed. This impact would be proportionally lower for total daily doses less than 3,000 mg/day.

No, SPRITAM must be taken with a sip of liquid. SPRITAM is intended to disintegrate in the mouth when taken with a sip of liquid. Please refer to the administration instructions in the US Full Prescribing Information for more details regarding the proper dosing and administration of SPRITAM including administration by Nasogastric or Gastrostomy tube.

• SPRITAM can be taken with a sip of liquid. In a study involving 33 subjects*, the average sip volume was approximately 1 tablespoon, or 15 mL, of water.
• SPRITAM can also be taken with a small amount of liquid in a cup, 1 tablespoon or enough liquid to cover the medicine.
• SPRITAM may also be administered via nasogastric or gastrostomy feeding tube (French size 10 to 14). Place the required number of whole tablets in a dosing cup with approximately 10 mL of room temperature water and gently swirl until the tablets disperse. Draw up the mixture into a 10 mL oral catheter-tip syringe, hold the syringe vertically, and administer immediately via feeding tube. Flush the feeding tube twice after administration by repeating this method with an additional 10 mL of room temperature water in the same dosing cup to ensure complete delivery of any remaining tablet residue, in the feeding tube.

Please refer to complete dosing and administration instructions in the US Full Prescribing Information for more information.

*Boudriau S, Harvey C, Massicotte J, et al. Randomized Comparative bioavailability of a novel three-dimensional printed fast-melt formulation of levetiracetam following the administration of a single 1000-mg dose to healthy human volunteers under fasting and fed conditions, Drugs R D. 2016;16(2):229–238.

Yes. Because SPRITAM is made using 3D printing, which does not use compression forces, it is normal to see a small amount of residual powder remaining in the blister pack.

SPRITAM is manufactured by Aprecia Pharmaceuticals, located in Mason, Ohio, USA. The manufacturing facility is the first and only in the world to have commercial scale, GMP-compliant equipment and processes for three-dimensionally printed, FDA-approved pharmaceutical products.